The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

NSC-132313     1,2-bis(oxiran-2-yl)ethane- 1,2-diol

Synonyms: AGN-PC-00Q6CZ, KB-81422, NSC132313, NSC 132313, Diepoxydulcitol, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dianhydrodulcitol


High impact information on Dianhydrodulcitol


Chemical compound and disease context of Dianhydrodulcitol


Biological context of Dianhydrodulcitol


Anatomical context of Dianhydrodulcitol


Associations of Dianhydrodulcitol with other chemical compounds


Gene context of Dianhydrodulcitol

  • The same dose of dianhydrodulcitol (DAD) produced a lower mortality rate among germfree mice than among SPF or conventional C3H mice [25].
  • We conclude that the addition of substantial and toxic doses of dianhydrogalactitol to DDP failed to substantially enhance the rate, quality, or duration of response compared to DDP alone [26].

Analytical, diagnostic and therapeutic context of Dianhydrodulcitol


  1. Dianhydrogalactitol and radiation therapy. Treatment of supratentorial glioma. Eagan, R.T., Childs, D.S., Layton, D.D., Laws, E.R., Bisel, H.F., Holbrook, M.A., Fleming, T.R. JAMA (1979) [Pubmed]
  2. Enhanced cell killing through the use of cell kinetics-directed treatment schedules for two-drug combinations in vitro. Barranco, S.C., May, J.T., Boerwinkle, W., Nichols, S., Hokanson, K.M., Schumann, J., Göhde, W., Bryant, J., Guseman, L.F. Cancer Res. (1982) [Pubmed]
  3. Mutagenicity of dibromodulcitol (DBD), an alkylating anticancer drug) and its mono- and bifunctional conversion products studied by the Salmonella/microsome assay. Tóth, K., Sugár, J., Somfai-Relle, S., Hedegüs, L. Carcinogenesis (1982) [Pubmed]
  4. Cell killing, kinetics, and recovery responses induced by 1,2:5,6-dianhydrogalactitol in dividing and nondividiing cells in vitro. Barranco, S.C., Flournoy, D.R. J. Natl. Cancer Inst. (1977) [Pubmed]
  5. A preliminary Pharmacokinetic study of dianhydrogalactitol (NSC-132313) disposition in the dog. Kimura, T., Sternson, L.A., Stella, V.J., Higuchi, T. J. Natl. Cancer Inst. (1977) [Pubmed]
  6. Alkylation by 1,2:5,6-dianhydrogalactitol of deoxyribonucleic acid and guanosine. Institóris, E., Tamás, J. Biochem. J. (1980) [Pubmed]
  7. Drug sensitivity studies on clonal cell lines isolated from heteroploid tumour cell populations. I. Dose response of clones growing in monolayer cultures. Pályi, I., Oláh, E., Sugár, J. Int. J. Cancer (1977) [Pubmed]
  8. Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer. Creagan, E.T., Eagan, R.T., Kvols, L.K. Oncology (1981) [Pubmed]
  9. Effect of phase I and II chemotherapeutic agents against human lymphomas heterotransplanted in nude mice. Sordillo, P.P., Helson, C., Lesser, M., Helson, L. Oncology (1983) [Pubmed]
  10. Dominance of resistance to the alkylating agent 1,2:5,6-dianhydrogalactitol in P388 mouse lymphoma hybrid cells. Pályi, I., Bence, J., Szikla, K., Hullán, L. Cancer Chemother. Pharmacol. (1989) [Pubmed]
  11. Human meningeal sarcoma heterotransplants in Nu/Nu mice treated with L-phenylalanine mustard (L-PAM) and dianhydrogalactitol (DAG). Member, B., Helson, L., Helson, C., Erlandson, R., Hajdu, S.I. Anticancer Res. (1985) [Pubmed]
  12. Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation. Eagan, R.T., Dinapoli, R.P., Hermann, R.C., Groover, R.V., Layton, D.D., Scott, M. Cancer treatment reports. (1982) [Pubmed]
  13. Pharmacokinetic studies on Elobromol in children with brain tumors. Paál, C., Erdélyi-Tóth, V., Pap, E., Csáki, C., Ferencz, T., Schuler, D., Borsi, J.D. Anticancer Drugs (1994) [Pubmed]
  14. Bacterial translocation in dianhydrodulcitol-treated mice. Anderlik, P., Szeri, I., Bános, Z. Acta Microbiol. Hung. (1988) [Pubmed]
  15. Acute effect of endogenous inhibitors and exogenous cytostatics on the ultrastructure of bone marrow cells. II. Single dose of granulocyte crude extract (GCE). Balázs, A. Haematologia (Budap) (1976) [Pubmed]
  16. Drug sensitivity studies on clonal cell lines isolated from heteroploid tumor cell population. II. Sensitivity of clones growing in suspension cultures. Pályi, I. Neoplasma (1980) [Pubmed]
  17. Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma. A Gynecologic Oncology Group study. Stehman, F.B., Blessing, J.A., Homesley, H.D., Currie, J.L., Yordan, E.L. Investigational new drugs. (1984) [Pubmed]
  18. Effect of a single high dose and repeated small doses of dianhydrogalactitol (DAG; NSC-132313) on rat intestinal mucosa. Kralovánszky, J., Prajda, N., Kerpel-Fronius, S., Gál, F., Szentirmay, Z. Cancer Chemother. Pharmacol. (1983) [Pubmed]
  19. Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol. Levin, V.A., Wheeler, K.T. Cancer Chemother. Pharmacol. (1982) [Pubmed]
  20. Cytokinetics of a human neuroblastoma cell line following treatment with dianhydrogalactitol. Sordillo, P.P., Andreeff, M., Helson, L., Steinmetz, J., Melamed, M.R. Cancer Invest. (1985) [Pubmed]
  21. Enzymological and morphological changes in rat intestinal mucosa following treatment with alkylating sugar alcohol derivatives. Prajda, N., Kralovánszky, J., Kerpel-Fronius, S., Gál, F., Szentirmay, Z. Anticancer Res. (1985) [Pubmed]
  22. Clinical trials with the hexitol derivatives in the U.S. Chiuten, D.F., Rozencweig, M., Von Hoff, D.D., Muggia, F.M. Cancer (1981) [Pubmed]
  23. Autologous bone marrow transplantation. A maximal therapy design for disseminated neuroblastoma. Helson, L. The American journal of pediatric hematology/oncology. (1985) [Pubmed]
  24. Immunomodulatory effect of synthetic branched polypeptides. II. Gaál, D., Hudecz, F., Kovács, A.L., Szekerke, M. Journal of biological response modifiers. (1986) [Pubmed]
  25. Higher resistance of germfree mice to dianhydrodulcitol, a lymphotropic cytostatic agent. Anderlik, P., Szeri, I., Bános, Z., Wessely, M., Radnai, B. Acta microbiologica Academiae Scientiarum Hungaricae. (1982) [Pubmed]
  26. Dianhydrogalactitol and cisplatin in combination for advanced cancer of the uterine cervix. Vogl, S.E., Seltzer, V., Camacho, F., Calanog, A. Cancer treatment reports. (1982) [Pubmed]
  27. Use of 1,2:5,6-dianhydrogalactitol in studies on cell kinetics-directed chemotherapy schedules in human tumors in vivo. Barranco, S.C., Townsend, C.M., Costanzi, J.J., May, J.T., Baltz, R., O'Quinn, A.G., Leipzig, B., Hokanson, K.M., Guseman, L.F., Boerwinkle, W.R. Cancer Res. (1982) [Pubmed]
  28. Effects of some sugar alcohol derivatives on mutation and induction of sister chromatid exchanges. Oláh, E., Tóth, K., Sugár, J., Hegedüs, L., Somfai-Relle, S. Cancer Res. (1983) [Pubmed]
  29. Gas-chromatographic analysis for 1,2:5,6-dianhydrogalactitol, an anti-neoplastic agent, in plasma. Kimura, T., Sternson, L.A., Higuchi, T. Clin. Chem. (1976) [Pubmed]
WikiGenes - Universities